Brookfield Corp’s Immunovant IMVT Stock Holding History

Brookfield Corp’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-100,000	Closed	-$1.6M	–	593
2021 Q1	$1.6M	Buy	+100,000	New	+$2.64M	0.01%	312

Other funds holding IMVT

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Brookfield Corp's IMVT Position: Q2 2021 in Review

Brookfield Corp sold out of Immunovant (IMVT) in Q2 2021, closing a stake of 100,000 shares — an estimated $1.6M sold.

Brookfield Corp first reported a position in IMVT in Q1 2021 and held it in 1 quarter. The position peaked at $1.6M in Q1 2021. 110 funds tracked by Wall St. Rank hold IMVT as of Q2 2021.

Brookfield Corp reported no remaining Immunovant position as of Q2 2021 after selling out during the quarter.
Brookfield Corp sold 100,000 Immunovant shares in Q2 2021, an estimated $1.6M.
Brookfield Corp first reported a position in Immunovant in Q1 2021 and held it in 1 quarter.
Brookfield Corp's Immunovant position peaked at $1.6M in Q1 2021.
110 funds tracked by Wall St. Rank held Immunovant as of Q2 2021.

Based on Brookfield Corp's 13F filing for Q2 2021, filed 17 Aug 2021.